Endocrine Abstracts

Background: Obesity (BMI< 30 kg/m2) is a chronic and progressive disease, that is associated with many co-morbidities such as cardiovascular and psychiatric diseases, cancer, and arthritis. Lifestyle interventions are the cornerstone of obesity treatment, but when ineffective, anti-obesity pharmacotherapy could be added. In recent years, several anti-obesity agents have been approved, such as the glucagon-like peptide -1 (GLP-1) analogue liraglutide. Liraglutide...